Focus: Ipsen is a mid-size biopharmaceutical company headquartered in Tianjin, China, with 1,001–5,000 employees specializing in small molecules and biologics across oncology, endocrinology, neurology, and gastroenterology. The company generates 73% of revenue from its flagship product AURYXIA (ferric citrate), indicating heavy reliance on a single asset.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Hot — 183 jobs added in 30d
Net +68 (183 new, 115 removed). Aggressive expansion phase.
Ipsen offers stable specialty pharma exposure with a diversified pipeline, but the imminent AURYXIA patent cliff and lack of visible hiring demand make this a high-risk career move unless you have specific expertise in oncology, liver disease, or botulinum toxin applications.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ipsen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ipsen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product accounting for 73% of company revenue; approaching patent cliff in July 2030 creates material revenue headwind.
Second-largest revenue contributor; somatostatin analog with established clinical use; LOE timeline not disclosed but likely approaching.
ANDA generic product post-LOE; minimal revenue contribution.
Rare disease therapeutic with extended LOE runway (November 2041); Phase 3 ongoing in biliary atresia signals growth potential.
Approved competitor to Botox; recent dual Phase 3 migraine wins (July 2026) position product for label expansion and revenue growth.
Nanoparticle oncology asset with extended patent protection (October 2036); modest current revenue.
ANDA NSAID generic; minimal strategic value post-LOE.
BLA biologic for rare pediatric growth disorder; narrow indication limits revenue scale.
First-in-class retinoid for rare genetic bone disorder; Phase 2 expansion signals label extension ambition; LOE June 2037.
PPAR agonist for rare liver disease; Phase 3 study underway; LOE March 2037; expansion potential in NASH/fibrosis space.
2 discontinued, 1 duplicate formulations not shown
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026 - GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026 GlobeNewswire
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline - GlobeNewswire
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline GlobeNewswire
Ipsen Pharma - Via Ritzau
Ipsen Pharma Via Ritzau
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market - BioSpace
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market BioSpace
Ipsen buys Kartos to add a Phase III drug for patients whose treatment falls short - Stock Titan
Ipsen buys Kartos to add a Phase III drug for patients whose treatment falls short Stock Titan
IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026 - GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026 GlobeNewswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative database.
A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo